Leading expert in colorectal cancer genetics, Dr. C. Richard Boland, MD, explains how microsatellite instability (MSI) impacts treatment selection and prognosis in colon cancer. He details how 15% of colorectal tumors exhibit this genetic signature, why MSI testing is crucial for personalized therapy, and how these tumors respond differently to chemotherapy compared to microsatellite-stable cancers.
More from Diagnostic Detectives Network
Microsatellite Instability in Colorectal Cancer: Key to Precision Treatment Decisions
Jump To Section
- What Is Microsatellite Instability?
- Discovery and Historical Context
- How MSI Testing Works
- MSI and Lynch Syndrome Connection
- Chemotherapy Response in MSI Tumors
- Prognostic Implications of MSI
- Personalized Treatment Approach
- Full Transcript
What Is Microsatellite Instability?
Microsatellite instability (MSI) is a genetic signature found in approximately 15% of colorectal cancers, representing a distinct molecular subtype. Dr. C. Richard Boland, MD explains that MSI occurs when tumor cells cannot properly replicate short repetitive DNA sequences called microsatellites due to defective DNA mismatch repair activity.
These microsatellites consist of repeating nucleotide patterns (like AAAAA or CACACACA) that normally remain stable during cell division. When mismatch repair fails, tumors accumulate hundreds of thousands of mutations in these sequences, creating the MSI hallmark that significantly impacts treatment decisions.
Discovery and Historical Context
Before the mid-1990s, Dr. C. Boland, MD, notes that colorectal cancer classification relied solely on microscopic features like tumor differentiation - characteristics that offered little therapeutic guidance. The discovery of MSI revolutionized colorectal cancer understanding by introducing molecular diagnostics.
Dr. C. Richard Boland, MD emphasizes this breakthrough allowed clinicians to move beyond crude morphological assessments to precise genetic profiling that directly informs treatment strategies and predicts patient outcomes.
How MSI Testing Works
Current MSI testing examines specific microsatellite sequences highly sensitive to mismatch repair defects. Dr. C. Boland, MD, explains the diagnostic criteria: "If there are two or more mutated microsatellite sequences, that's microsatellite instability."
This simple yet powerful test identifies both inherited Lynch syndrome cancers (caused by germline mismatch repair mutations) and sporadic cases (often caused by MLH1 gene silencing through methylation). The test's clinical utility extends beyond diagnosis to therapeutic decision-making.
MSI and Lynch Syndrome Connection
Dr. C. Richard Boland, MD highlights that MSI testing initially helped identify nearly all Lynch syndrome cases, an inherited condition accounting for about 3% of colorectal cancers. The same test also detects an additional 12% of sporadic colorectal cancers with epigenetic MLH1 silencing.
This dual diagnostic capability makes MSI testing invaluable for both genetic counseling in families and treatment planning for individual patients, creating a bridge between hereditary cancer risk assessment and precision oncology.
Chemotherapy Response in MSI Tumors
MSI status critically influences chemotherapy outcomes. Dr. Boland reveals the paradigm-shifting finding: "Tumors with microsatellite instability did not get any additional benefit from chemotherapy - there was additional harm." This counterintuitive response pattern necessitates treatment personalization.
Research shows 5-fluorouracil-based regimens, standard for microsatellite-stable tumors, may actually worsen outcomes in MSI-high colorectal cancers, prompting alternative treatment approaches for this molecular subtype.
Prognostic Implications of MSI
Despite their poor chemotherapy response, MSI-high colorectal cancers generally have better natural histories. Dr. C. Richard Boland, MD describes this as "two competing phenomena" - while these tumors are inherently less aggressive, conventional treatments may negate their survival advantage.
Studies demonstrate MSI-high patients often have improved survival when untreated or when receiving immunotherapy instead of traditional chemotherapy, highlighting the importance of accurate molecular classification before treatment initiation.
Personalized Treatment Approach
Dr. Boland positions MSI testing as the first critical step in colorectal cancer precision medicine. "That was the first step into personalized medicine for colorectal cancer treatment," he states, emphasizing how molecular stratification guides therapeutic decisions.
Current guidelines recommend MSI testing for all colorectal cancers, as results determine eligibility for both chemotherapy avoidance and emerging immunotherapies that show particular promise for MSI-high tumors due to their high mutational burden.
Full Transcript
Dr. Anton Titov, MD: What is microsatellite instability in colorectal cancer? What does high microsatellite instability mean for cancer prognosis? How do we select chemotherapy in cancer patients with high microsatellite instability?
Dr. C. Boland, MD: Precision medicine in treatment of colorectal cancer means we have to separate the notion of colon cancer as one entity into many colon cancers that differ by distinct molecular nature of the tumors. About 15% of colorectal cancer tumors have a specific genetic change called microsatellite instability. Microsatellite instability in colon cancer is very important for treatment selection and prognosis.
Dr. Anton Titov, MD: What is microsatellite instability in colon cancer? What is the role of microsatellite instability for personalizing the treatment and assessing prognosis in colorectal cancer?
Dr. C. Boland, MD: Excellent question! Let's go back and get a little historical perspective. In the old days, before the mid-1990s, the only characteristics we could use to distinguish one colon cancer from another were: was it well-differentiated or poorly differentiated and making a lot of mucin? None of those things were terribly helpful. We didn't use them at all for any therapeutic decisions.
Then microsatellite instability was discovered in colorectal cancer tumors. Microsatellite instability is a type of genetic signature. Microsatellite sequences are short repetitive nucleotide sequences in DNA. For example, a whole series of adenines in a row or a whole series of CA nucleotides that are repeated over and over in DNA.
Microsatellite sequences are replicated exactly from parent cell to daughter cell. But they require the DNA mismatch repair system for replication to happen properly. So in cancers with defective DNA mismatch repair activity, cells cannot replicate those sequences well. The tumor gets hundreds of thousands of mutations in these microsatellite sequences.
We selected microsatellite sequences that are very sensitive to the loss of DNA mismatch repair activity. You can then do a simple test. If there are two or more microsatellite sequences that are mutated, that's microsatellite instability.
Dr. C. Boland, MD: The first thing we found led us to almost all of the Lynch syndrome colon cancers and another 12% of colorectal cancer cases that had gene silencing caused by methylation of MLH1 gene. That told us about inheritance of colorectal cancer in families.
We also realized that tumors with microsatellite instability did not respond in the same way to chemotherapy. They did not get any additional benefit from chemotherapy. There was additional harm from chemotherapy in colon cancer with microsatellite instability.
But also, colon cancers with microsatellite instability had a better natural history. So there were two competing phenomena. Patients with microsatellite instability in colorectal tumors were more likely to survive cancer. But we were also unlikely to help these patients by treating them with standard chemotherapy.
That was the first step into personalized medicine for colorectal cancer treatment.